Evidence map›Paper›PMID 35596017›Full record

ArticleWorld journal of urology2022

Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.

Ekaterina Laukhtina, Axelle Boehm, Benoit Peyronnet, Carlo Andrea Bravi, Jose Batista Da Costa, Francesco Soria, David D'Andrea, Pawel Rajwa, Fahad Quhal, Takafumi Yanagisawa and 14 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 14 institutions in 13 countries.

Ekaterina Laukhtina *Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-8953-0272
Axelle Boehm *Department of Urology, University Hospital of Tours, Tours, France.
Benoit PeyronnetDepartment of Urology, University Hospital of Rennes, Rennes, France.
Carlo Andrea BraviUnit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Jose Batista Da CostaDepartment of Urology, University Hospital Henri Mondor, AP-HP, UPEC, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 95010, Créteil Cedex, France.
Francesco SoriaDivision of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Turin, Italy.
David D'AndreaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Pawel RajwaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Fahad QuhalDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Takafumi YanagisawaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Frederik KönigDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Hadi MostafaeiDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Dmitry EnikeevInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Alexandre IngelsDepartment of Urology, University Hospital Henri Mondor, AP-HP, UPEC, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 95010, Créteil Cedex, France.
Gregory VerhoestDepartment of Urology, University Hospital of Rennes, Rennes, France.
Frederiek D'HondtDepartment of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
Alexandre MottrieDepartment of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
Steven JoniauDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Hendrik Van PoppelDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Alexandre de la TailleDepartment of Urology, University Hospital Henri Mondor, AP-HP, UPEC, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 95010, Créteil Cedex, France.
Karim BensalahDepartment of Urology, University Hospital of Rennes, Rennes, France.
Franck BruyèreDepartment of Urology, University Hospital of Tours, Tours, France.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Benjamin PradereDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. benjaminpradere@gmail.com.
Centre Hospitalier Universitaire de Rennes · FROnze Lieve Vrouwziekenhuis Hospital · BEUniversité Paris-Est Créteil · FRComprehensive Cancer Center Vienna · ATKU Leuven · BESechenov University · RUUniversité de Tours · FRAl-Ahliyya Amman University · JOAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITJikei University School of Medicine · JPKing Fahad Specialist Hospital · SAMedical University of Silesia · PLTabriz University of Medical Sciences · IRUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe optimal management of the urethra in patients planned for radical cystectomy (RC) remains unclear. We sought to evaluate the impact of urethrectomy on perioperative and oncological outcomes in patients treated with RC for non-metastatic urothelial carcinoma of the bladder (UCB). MATERIALS AND

methodsWe assessed the retrospective data from patients treated with RC for UCB of five European University Hospitals. Associations of urethrectomy with progression-free (PFS), cancer-free (CSS), and overall (OS) survivals were assessed in univariable and multivariable Cox regression models. We performed a subgroup analysis in patients at high risk for urethral recurrence (UR) (urethral invasion and/or bladder neck invasion and/or multifocality and/or prostatic urethra involvement).

resultsA total of 887 non-metastatic UCB patients were included. Among them, 146 patients underwent urethrectomy at the time of RC. Urethrectomy was performed more often in patients with urethral invasion, T3/4 tumor stage, CIS, positive frozen section analysis of the urethra, and those who received neoadjuvant chemotherapy, underwent robotic RC, and/or received an ileal conduit urinary diversion (all p < 0.001). Estimated blood loss and the postoperative complication rate were comparable between patients who received an urethrectomy and those who did not. Urethrectomy during RC was not associated with PFS (HR 0.83, p = 0.17), CSS (HR 0.93, p = 0.67), or OS (HR 1.08, p = 0.58). In the subgroup of 276 patients at high risk for UR, urethrectomy at the time of RC decreased the risk of progression (HR 0.58, p = 0.04).

conclusionIn our study, urethrectomy at the time of RC seems to benefit only patients at high risk for UR. Adequate risk assessment of UCB patients' history may allow for better clinical decision-making and patient counseling.

Indexed as

Carcinoma, Transitional CellUrethral NeoplasmsUrinary Bladder NeoplasmsCystectomyHumansMaleRetrospective StudiesUrethraUrinary BladderBladder cancerRadical cystectomyUrethral recurrenceUrethrectomy

Identifiers

PMID35596017
PMCPMC9236994
OpenAlexW4281257937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.